- Home
- NRGV vs ERAS Comparison
NRGV vs ERAS Comparison
Compare NRGV & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRGV
- ERAS
- Stock Information
- Founded
- NRGV 2017
- ERAS 2018
- Country
- NRGV United States
- ERAS United States
- Employees
- NRGV N/A
- ERAS N/A
- Industry
- NRGV Industrial Machinery/Components
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- NRGV Miscellaneous
- ERAS Health Care
- Exchange
- NRGV Nasdaq
- ERAS Nasdaq
- Market Cap
- NRGV 491.6M
- ERAS 439.7M
- IPO Year
- NRGV N/A
- ERAS 2021
- Fundamental
- Price
- NRGV $3.33
- ERAS $3.18
- Analyst Decision
- NRGV Hold
- ERAS Buy
- Analyst Count
- NRGV 2
- ERAS 6
- Target Price
- NRGV $1.75
- ERAS $3.50
- AVG Volume (30 Days)
- NRGV 3.5M
- ERAS 1.6M
- Earning Date
- NRGV 11-10-2025
- ERAS 11-12-2025
- Dividend Yield
- NRGV N/A
- ERAS N/A
- EPS Growth
- NRGV N/A
- ERAS N/A
- EPS
- NRGV N/A
- ERAS N/A
- Revenue
- NRGV $83,836,000.00
- ERAS N/A
- Revenue This Year
- NRGV $314.68
- ERAS N/A
- Revenue Next Year
- NRGV $38.97
- ERAS N/A
- P/E Ratio
- NRGV N/A
- ERAS N/A
- Revenue Growth
- NRGV N/A
- ERAS N/A
- 52 Week Low
- NRGV $0.60
- ERAS $1.01
- 52 Week High
- NRGV $4.85
- ERAS $3.30
- Technical
- Relative Strength Index (RSI)
- NRGV 51.58
- ERAS 72.03
- Support Level
- NRGV $3.07
- ERAS $2.83
- Resistance Level
- NRGV $3.53
- ERAS $3.08
- Average True Range (ATR)
- NRGV 0.39
- ERAS 0.22
- MACD
- NRGV -0.03
- ERAS 0.05
- Stochastic Oscillator
- NRGV 23.87
- ERAS 94.47
About NRGV Energy Vault Holdings Inc.
Energy Vault Holdings Inc is a grid-scale energy storage company that is driving a faster transition to renewable power by solving the intermittence issues that are inherent to the prevalent sources of renewable energy, solar and wind. Geographical presence in United States, China and Other. Majority of its revenue comes from U.S.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.